Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $298.00

Repligen Co. (NASDAQ:RGEN) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $306.00.

Several equities analysts recently commented on RGEN shares. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating and set a $305.00 price target on the stock. in a report on Tuesday, September 28th. Stephens boosted their price target on shares of Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 20th. Craig Hallum boosted their price target on shares of Repligen from $258.00 to $368.00 and gave the company a “buy” rating in a report on Monday, September 27th. BNP Paribas began coverage on shares of Repligen in a report on Thursday. They issued an “outperform” rating and a $330.00 price target on the stock. Finally, Exane BNP Paribas began coverage on shares of Repligen in a report on Thursday. They issued an “outperform” rating and a $330.00 target price on the stock.

NASDAQ:RGEN traded up $14.11 during trading hours on Friday, hitting $267.12. 12,797 shares of the company traded hands, compared to its average volume of 388,519. The stock has a market capitalization of $14.67 billion, a price-to-earnings ratio of 146.31 and a beta of 0.90. Repligen has a twelve month low of $162.29 and a twelve month high of $327.32. The firm has a 50-day moving average of $278.91 and a 200 day moving average of $227.01.

Repligen (NASDAQ:RGEN) last released its earnings results on Monday, July 26th. The biotechnology company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.27. The firm had revenue of $162.96 million during the quarter, compared to analysts’ expectations of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. The business’s quarterly revenue was up 86.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.42 EPS. On average, analysts expect that Repligen will post 2.76 EPS for the current year.

In related news, Director Karen A. Dawes sold 274 shares of the business’s stock in a transaction dated Tuesday, September 14th. The stock was sold at an average price of $294.26, for a total value of $80,627.24. Following the completion of the transaction, the director now owns 93,908 shares of the company’s stock, valued at $27,633,368.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 25,000 shares of Repligen stock in a transaction dated Thursday, September 9th. The shares were sold at an average price of $294.75, for a total value of $7,368,750.00. Following the completion of the transaction, the chief executive officer now owns 214,495 shares in the company, valued at approximately $63,222,401.25. The disclosure for this sale can be found here. Insiders have sold 52,154 shares of company stock valued at $14,144,680 in the last three months. Insiders own 1.20% of the company’s stock.

Large investors have recently modified their holdings of the company. RPg Family Wealth Advisory LLC bought a new stake in Repligen during the second quarter worth $27,000. Creative Financial Designs Inc. ADV lifted its holdings in Repligen by 50.0% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 50 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Repligen during the 2nd quarter worth about $37,000. Rational Advisors LLC purchased a new stake in shares of Repligen in the 2nd quarter valued at about $48,000. Finally, Huntington National Bank raised its holdings in shares of Repligen by 45.5% in the 2nd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 91 shares in the last quarter. 83.82% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Story: What sectors are represented in the Hang Seng index?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.